All In Biotech

Drug Trial Radar · NCT06588738

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 862 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

862

Actual

Start

Aug 20, 2024

Primary completion

Sep 23, 2025

Study completion Dec 18, 2025

Sponsor

Lead sponsor
Alumis IncIndustry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.

Conditions

  • Plaque Psoriasis

Interventions

  • EnvudeucitinibDrug

    ESK-001

  • PlaceboDrug

    Placebo

  • ApremilastDrug

    Apremilast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placeboTime frame: 16 weeks

Locations

124 sites in 12 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center, PC

    Birmingham, Alabama

  • Chandler Clinical Trials

    Chandler, Arizona

  • Noble Clinical Research

    Tucson, Arizona

  • Zenith Research Inc.

    Beverly Hills, California

  • Raoof MD

    Encino, California

  • Long Beach Research Institute

    Long Beach, California

  • Dermatology Research Associates

    Los Angeles, California

  • Empire Clinical Research - Pomona

    Pomona, California

  • Integrative Skin Science and Research

    Sacramento, California

  • UC San Diego

    San Diego, California

  • Southern California Clinical Research

    Santa Ana, California

  • Clinical Science Institute Dermatology Institute

    Santa Monica, California

  • FXM Clinical Research Ft. Lauderdale LLC

    Fort Lauderdale, Florida

  • Direct Helpers Research Center (DHRC)

    Hialeah, Florida

  • AppleMed Research Group under WCG

    Miami, Florida

  • FAX Pharma Clinical Research Inc

    Miami, Florida

  • FXM Clinical Research - Miami LLC

    Miami, Florida

  • Las Mercedes Medical Research

    Miami, Florida

  • FXM Clinical Research Miramar LLC

    Miramar, Florida

  • Renstar Medical Research

    Ocala, Florida

  • DS Research of Southern Indiana

    Clarksville, Indiana

  • The Indiana Clinical Trials Center

    Plainfield, Indiana

  • DS Research of Kentucky

    Louisville, Kentucky

  • Michigan Center for Research Company

    Clarkston, Michigan

  • Henry Ford Medical Center - Farmington Road

    Detroit, Michigan

  • Revival Research Institute

    Troy, Michigan

  • Grekin Skin Institute

    Warren, Michigan

  • Associated Skin Care Specialists - Minnesota Clinical Study Center

    New Brighton, Minnesota

  • Schlessinger MD

    Omaha, Nebraska

  • Las Vegas Clinical Trials

    Las Vegas, Nevada

  • NYC Health and Hospitals Elmhurst

    Elmhurst, New York

  • Pioneer Clinical Research NY

    New York, New York

  • Cameron Dermatology

    New York, New York

  • DermResearchCenter of New York

    Stony Brook, New York

  • Asheville Clinical Trials

    Asheville, North Carolina

  • WDC Cosmetic and Research

    Wilmington, North Carolina

  • Optima Research Boardman

    Boardman, Ohio

  • Clinical Partners LLC

    Johnston, Rhode Island

  • Modern Research Associates PLLC

    Dallas, Texas

  • SMS Clinical Research

    Mesquite, Texas

Showing 40 of 124 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.